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Abstract: The microorganisms that live symbiotically in human beings are increasingly recognized
as important players in health and disease. The largest collection of these microorganisms is found
in the gastrointestinal tract. Microbial composition reflects both genetic and lifestyle variables
of the host. This microbiota is in a dynamic balance with the host, exerting local and distant
effects. Microbial perturbation (dysbiosis) could contribute to the risk of developing health problems.
Various bacterial genes capable of producing estrogen-metabolizing enzymes have been identified.
Accordingly, gut microbiota is capable of modulating estrogen serum levels. Conversely, estrogen-like
compounds may promote the proliferation of certain species of bacteria. Therefore, a crosstalk
between microbiota and both endogenous hormones and estrogen-like compounds might synergize
to provide protection from disease but also to increase the risk of developing hormone-related
diseases. Recent research suggests that the microbiota of women with breast cancer differs from
that of healthy women, indicating that certain bacteria may be associated with cancer development
and with different responses to therapy. In this review, we discuss recent knowledge about the
microbiome and breast cancer, identifying specific characteristics of the human microbiome that may
serve to develop novel approaches for risk assessment, prevention and treatment for this disease.
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1. Introduction
The incidence of breast cancer (BC) worldwide has risen to unprecedented levels in recent decades,
making it the major cancer of women in many parts of the world nowadays [1]. It is not only the
most frequently diagnosed cancer (excluding non-melanoma skin cancers) among women worldwide,
affecting one in eight women during their lifetime, but also one of the leading causes of cancer mortality
in women, with more than 0.5 million deaths in 2012 (6.4% of total cancer deaths, globally, and 15.4% in
more developed countries) [2,3]. In 2012, BC accounted for approximately 1.7 million new cases (25% of
total cancer incidence, globally). Moreover, between 2008 and 2012 the incidence of BC increased by
20%, and mortality by 14% [4]. Rates are generally high in North America, Australia-New Zealand,
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and Northern and Western Europe; intermediate in Central and Eastern Europe, Latin America, and the
Caribbean; and low in most of Africa and Asia [5].
Cancer in general is a complex disease, where a multitude of genomic and physiological
alterations occur incessantly in the tumor tissue, contributing to the complexity of disease treatment
and management. For this reason, and regardless of efforts that have been achieved by extensive
research, the precise etiology for BC is still unknown, but the combination of genetic, epigenetic,
and environmental factors has been identified. Nevertheless, those genetic-epigenetic determinants
and well-established risk factors only could explain a limited amount of the global burden of this
disease [6]. As a result, the origin of a vast majority of breast cancer cases (estimated to be as high
as 70%) still remains unknown [7]. Therefore, it is crucial to understand how these sporadic breast
cancers arise in order to develop preventative strategies against this devastating disease.
Apart from genetic factors, such as inherited loss of the BRCA1/2 gene, several environmental
and lifestyle components have also been strongly related to BC. Although diet, alcohol, and radiation
have all been associated with increased incidence, the main identified risk factors are life exposure to
hormones including physiological variations associated with puberty, pregnancy, menopause, personal
choice of use of hormonal contraceptives and/or hormone replacement therapy [1]. BC risk is directly
related to higher levels of endogenous estrogens and differences in estrogen metabolism, especially
among postmenopausal women [8,9]. The decline associated with menopause in age-specific incidence
rates, known as the Clemmesen hook, is widely observed among women around the world [10,11].
Reproductive history, alcohol intake, obesity, and use of hormone therapy exert their effects, at least
in part, by modifying the time and intensity of the exposure of the mammary gland to steroidal
hormones [12]. This hormonal regulation manifests, both clinically and molecularly, as distinct
subtypes: Triple negative, HER2 positive (HER2+), and ER positive (ER+) [13].
Bacterial communities within the host could be one additional environmental factor related to
BC, which has been only recently considered in sporadic breast cancers of unknown etiology. In the
recent years, there has been a strong interest in fully characterizing the microbiota associated with
different parts of the body under different health conditions, due to the fact that different published
studies have shown that bacterial communities vary across body habitats, establishing complex
interactions between bacteria and the host [14,15]. These studies have been possible with the use of
deep-sequencing technologies (for example, pyrosequencing technique, which provides a qualitative
survey of relative abundances of microbiota, and quantitative polymerase chain reaction (qPCR) which
may determine quantitative differences), and also due to the findings from the Human Microbiome
Project analyses, which has demonstrated that the diversity and abundance of the signature microbes
in each habitat varied among healthy subjects, with strong niche specialization both within and among
individuals [14].
The terms microbiota and microbiome are often used as synonyms, but express two different
meanings: whereas microbiota refers to the totality of microbes (bacteria, archaea, fungi, viruses
and protozoa) in a particular environment, in other words, it refers to taxonomy and abundance of
community members, the microbiome is the totality of genomes of a microbiota and it is often used
to describe the entity of microbial traits (functions) encoded by a microbiota [16]. The improvement
of DNA-RNA sequencing methods has made possible to group microbiota composition into clusters,
known as Operational Taxonomic Units (OTUs), based on genetic sequence similarities of specific
taxonomic marker genes. Each OTU may belong to different phyla, but new methods that resolve
amplicon sequence variants (ASVs) from Illumina-scale amplicon data without imposing the
arbitrary dissimilarity thresholds that define molecular OTUs, have been recently developed [17–22].
ASV methods infer the biological sequences in the sample prior to the introduction of amplification
and sequencing errors and distinguish sequence variants differing by as little as one nucleotide [23].
The human microbiota is the term applied to the universe of microbes that live in different
habitats of our body (mostly the gut, skin, vagina and mouth, but also the nose, conjunctiva,
pharynx and urethra, among others). The microbiota of each organ is distinct, and there is an
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important and functionally relevant inter-individual variability of microbiomes, which makes them a
potential determinant of disease (including cancer) development [14]. Human bacterial composition
contributes and affects different diseases including metabolic disorders, inflammatory and autoimmune
diseases, and allergy [24], and even diseases where microbiota involvement seems unlikely [25,26].
The microbiota has been also implicated in cancer development progression and aggressiveness at
a variety of body sites [25,27] including stomach [28], colon [29], liver [30], lung [31], and skin [32].
Epidemiologic studies suggest that the human microflora contributes to 16–18% or more of worldwide
malignancies [33].
This review discusses important questions such as the role of the human microbiota in BC
development, its ability to modulate inflammation, immunity and metabolism, and the possibility that
both intestinal and local microbes could affect cancer prevention and be a new target for therapeutic
approaches, thus improving the prognosis and quality of life of breast cancer patients.
2. Gut Microbiota
The human gastrointestinal tract is colonized by a complex and diverse community composed
of trillions of individual microorganisms comprising 1014 heterogeneous species of bacteria,
viruses, archaea, and fungi [24]. Their collective bacterial genome harbors approximately 150-fold
more genes than the human genome [14]. So far, the human gastrointestinal tract is the best
investigated microbiota and is serving as a model for understanding host–microbiota interactions and
disease. Main phyla of the gut microbiota are Firmicutes, Bacteriodetes, Actinobacteria, Proteobacteria,
Fusobacteria, Verrucomicrobia, Tenericutes and Lentisphaerae; and main genera are Bacteroides, Clostridium,
Faecalibacterium, Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus, Lactobacillus, Streptococcus,
Streptomyces and Bifidobacterium [25].
The human gut microbiota is helpful in physiologic activities such as digestion, metabolism,
and homeostasis, and plays important roles in human health. For example, it is essential in digestion
and absorption of indigestible carbohydrates for humans (dietary fiber), production of vitamins B and
K, metabolism of endogenous and exogenous compounds, and immunity. It is also actively involved
in innate and cell-mediated immunity, helps to maintain intestinal barrier function, and assists with an
appropriate immune response against pathogenic microbes [25,34].
The composition of the intestinal microbiota is determined by several internal and external
factors, including age, race, diet, maternal colonization, and hygiene, as well as host genetics and
environmental exposures to xenobiotics and antibiotics [34,35]. For instance, dietary fiber has been
shown to affect the composition of gut bacteria and reduce intestinal β-glucuronidase activity, resulting
in a decreased deconjugation and reabsorption of estrogens [36]. Additionally, some individual factors
such as stress, travelling, or pharmacological treatment or drugs, can also directly and rapidly produce
changes [25]. This complexity represents a challenge to the goal of phenotyping all these populations
in each individual and comparing them with others [25].
A symbiotic relationship (referred to as normobiosis) between host and microbiota is critical
to maintaining a balance (homeostasis) in the gut. This symbiotic relationship confers benefits to
the host in many key aspects of life. However, any perturbation of the normal microbiome content
that disrupts this relationship, the so-called “dysbiosis”, may result in detrimental consequences for
the host, and promote different diseases [27]. Moreover, it is known that differential abundances of
certain microorganisms in the composition of the microbial community, and/or a discrete presence
of some bacterial species can exert pathogenic effects that encourage disease development. Thus,
Helicobacter pylori infection is known to promote gastric cancer and gastric mucosal-associated
lymphoid tissue (GALT) lymphoma [37], although H. pylori-mediated protection against extra-gastric
immune and inflammatory disorders has been described [38]. This pathogen bacterium is classified as
a carcinogen by the International Agency for Research on Cancer (IARC).
In contrast to gastric carcinogenesis, recent evidence suggests that human disease is attributable
not only to single pathogens but also to global changes in the microbiota [25]. In fact, altered
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host–gut microbiota interactions, caused by dysbiosis, seem to play an important role in colorectal
carcinogenesis [39]. In this context, decreasing overall diversity has been associated with colorectal
cancer [40]. Nevertheless, in colon cancer, the overabundance of a single bacterial species
(Fusobacterium nucleatum) has been correlated with disease and with increased likelihood of lymph
node metastasis [41]. But the bacterium Bacteroidetes fragilis exerts a protective effect against colitis by
modulating inflammatory immune responses in the gut [42].
The gastrointestinal tract exerts both local and long-distance effects in other parts of the body.
The liver does not contain a known microbiota and is a good example of a cancer that is promoted by
dysbiotic microbiota through long-distance mechanisms. Moreover, intestinal bacteria may promote
liver cancer through proinflammatory microorganism-associated molecular patterns (MAMPs) and
bacterial metabolites, both of which reach the liver via the portal vein [30,43].
In addition to modulating inflammation and influencing genomic stability of host cells through
the deregulation of different signals/pathways, gut microbiota has also been related with cancer
progression by affecting metabolic pathways of estrogens through enterohepatic circulation [25].
In this regard, it has been proposed that certain gut microbes may play a role in breast carcinogenesis
by promoting antitumor immunity and immune surveillance, and/or by modulating systemic estrogen
levels [44,45]. BC associations with estrogen levels could reflect differences among individuals in
their intestinal microbial communities [46], as shown 50 years ago by Adlercreutz and collaborators,
who demonstrated one of the fundamental roles of the gut microbiota [47]. More recently, Fuhrman
and co-workers demonstrated that postmenopausal estrogen metabolism is associated with microbial
diversity [13].
3. Is There a Link between Gut Microbiota and Breast Cancer?
The link between intestinal microbiota dysbiosis and breast cancer has been investigated in
several case-control studies, and many hypotheses have been suggested, some of which underline the
possible decrease in the metabolic ability of the microbiota and a weakness of the immune system [48].
The results of clinical studies on the relationship between gut microbiota and breast cancer are
summarized in Table 1. Most studies rely on the sequencing of a specific region within the bacterial
16S rRNA gene, with the exception of several studies that are based on either qPCR or a DNA array
(PathoChip) (Table 1).
The studies targeting at the relationship between BC and gut microbiota are quite limited so far.
In 2011, Plottel and Blaser [49] extensively discussed the so-called “estrobolome”, the collection of
the enteric bacterial genes whose products metabolize estrogen and its metabolites. Perturbations in
the microbiota/estrobolome can therefore lead to elevated levels of circulating estrogens and its
metabolites, thereby increasing the risk of BC. Indeed, clinical studies have identified associations
between the gut microbiota, and urinary estrogens and estrogen metabolites [13].
The metabolism of estrogens takes places in the liver, where they are conjugated and excreted into
the gastrointestinal lumen within the bile; there they are de-conjugated by bacterial β-glucuronidase,
and then they are re-absorbed as free estrogens through enterohepatic circulation, getting to different
organs like the breast [25]. These metabolites are produced through estrogen metabolism by several
bacteria included in Clostridia and Ruminococcaceae families [25]. In addition, others estrogen-like
metabolites can be also produced by oxidative and reductive reactions in the gut and by an induced
synthesis of estrogen-inducible growth factors, which might have a carcinogenic potential. Moreover,
bacterial β-glucuronidase could participate in the deconjugation of xenobiotics and/or xenoestrogens,
leading to their reuptake through the enterohepatic pathway and thus increasing the time they remain
in the organism [50]. Many β-glucuronidase bacteria are found in two dominant subgroups, namely
the Clostridium leptum cluster and the Clostridium coccoides cluster, which belong to the Firmicutes
phylum. The Escherichia/Shigella bacterial group, a member of the Proteobacteria phylum, also possesses
β-glucuronidase enzymes [51].
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Other studies have focused on the relationship between gut microbiome and BC risk through
estrogen-independent pathways [49,52,53]. An enteromammary pathway by which some bacteria
from the gut could reach the mammary gland via an endogenous route has been the most studied
pathway [54]. A case-control study comparing the fecal microbiota between BC patients and paired
controls found significantly altered microbiota composition and less diverse gut bacteria among
the postmenopausal BC patients [52]. The gut microbiome of case patients had higher levels of
Clostridiaceae, Faecalibacterium, and Ruminococcaceae; and lower levels of Dorea and Lachnospiraceae.
Moreover, the fecal microbiota was less diverse (α-diversity) in cancer patients. Total estrogens
correlated with α-diversity in control patients but not in case patients; and, unexpectedly, cancer
patients had higher but not statistically significant levels of systemic estrogens. A possible explanation
may involve other known breast cancer risk factors such as adiposity and obesity, since in these
circumstances the gut microbiota is less diversified [55].
The gut microbiota has been also related to the development of adiposity and obesity [55],
and it is known that overweight and obese women have a higher risk of BC compared to healthy
weight women, especially during the postmenopausal period [56]. Within the gut, Firmicutes and
Bacteroidetes are the two main phyla involved in the colonic metabolism of indigestible nutrients,
including dietary fibers and polyphenols [57]. Several studies have described a higher ratio of
Firmicutes/Bacteroidetes (F/B) in obese versus lean subjects, although with controversial results [58].
Significant differences in the absolute numbers of total bacteria and of three bacterial groups (Firmicutes,
Faecalibacterium prausnitzii, and Blautia) were observed in feces as a function of the body mass index
(BMI) of women with early-stage breast cancer, with lower number of bacteria in overweight and obese
patients [48]. The lower number of Firmicutes bacteria observed in overweight subjects contrasted with
other clinical studies showing an increased ratio (F/B) with obesity [59], no effect [60], or a decreased
ratio [61] in obese patients. The relation between these main phyla and BMI remains unclear [48].
Goedert and co-workers [53] investigated the role of immunity and inflammation in BC risk,
and whether the gut microbiota differed in the composition of immune-recognized microbiota in a
case-control study. Cases and controls had significantly different composition of the IgA+ microbiota.
When they divided cases into those with IgA+ and IgA− microbiota, cancer cases IgA+ had an altered
composition, lower richness and α-diversity of their fecal microbiota, significantly more marked than
cases with the IgA-negative microbiota, after adjustment for estrogen levels and other variables [53].
Distributions of estrogen metabolites versus parent estrogen (potentially reflecting differences in
estrogen metabolism) were essentially identical in cases and controls. Levels of parent estrogens
(estrone and estradiol) and major estrogen metabolites were all non-significantly higher in cases
compared with controls [53]. Compared to controls, postmenopausal breast cancer women had
significant and different estrogen-independent associations with the IgA+ and IgA− gut microbiota,
suggesting that the gut microbiota may influence BC risk by altered metabolism, estrogen recycling,
and immune pathways.
Bard and colleagues [62] also evaluated the composition of the gut microbiota among BC patients
with different clinical characteristics. The majority of the participants were early-stage invasive
ductal carcinoma. Patients with grade III cancer (n = 7) had higher absolute numbers of Blautia spp.
compared with grade I patients (p = 0.048). In addition, absolute numbers of Bifidobacterium and
Blautia, and proportions of Faecalibacterium Prausnitzii and Blautia, varied according to clinical stages,
suggesting that gut microbiota may be related with the development and evolution of BC. In this study,
significant differences were also observed for absolute numbers of total bacteria and for some studied
bacterial groups (F. Prausnitzii, Firmicutes, Blautia and Egerthella) according to BMI [62].
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Table 1. Human studies dealing with microbiota and breast cancer.
Study Sampling Materials and Site Microbiota Detection and OTUPicking Method * Sample Size Main Findings
Fuhrman et al., 2014 [13] Urine and feces of healthypostmenopausal women
Pyrosequencing V1-V2 16S rRNA
amplicons, QIIME: Ribosomal Data
Project Bayesian classifier, specific
method not disclosed
60 healthy postmenopausal
women
The composition and diversity of the gut
microbiota were associated with patterns of
estrogen metabolism.
Relative abundances of the order Clostridiales
and the genus Bacteroides were directly and
inversely related with the ratio estrogen
metabolites to estrogen parents, respectively.
Associations were independent of age, body
mass index, and other study design factors.
Xuan et al., 2014 [44]
Breast tumor tissue and paired
normal adjacent tissue from the
same women
Pyrosequencing gDNA amplified
16S V4 rDNA, QIIME: Greengenes
database, specific method not
disclosed
20 patients with ER+ BC
Proteobacteria, Firmicutes, Actinobacteria,
Bacteroidetes and Verrucomicrobia accounted for
96.6% of the microbiota composition.
The amount of bacteria was not significantly
different in normal tissue from breast cancer
women compared with healthy individuals.
However, Methylobacterium radiotolerans was
the most significantly enriched and the most
prevalent (100% of samples) in tumor tissues,
and Sphingomonas yanoikuyae (95% of samples)
in paired normal tissues. The relative
abundances of these two bacterial species were
inversely correlated in paired normal tissue
but not in tumor tissue, indicating that
dysbiosis was associated with cancer.
Urbaniak et al., 2014 [63]
Breast tumor tissue from
lumpectomies, mastectomies
and breast reductions
Ion Torrent V6 16S rRNA
sequencing, UCLUST: Taxonomic
assignments for each OTU were
made by the Ribosomal Database
Project SeqMatch tool. The 16S
rRNA sequences obtained in this
study have been deposited in the
Short Read Archive at NCBI.
81 Canadian and Irish women
[43 Canadian (11 benign, 27 BC,
5 healthy) and 38 Irish (33 BC,
5 healthy)]
Proteobacteria and Firmicutes were the most
abundant phyla in the whole study population.
The most abundant taxa in Canadian samples
were Bacillus (11.4%) and Acinetobacter (10.0%);
and unclassified Enterobacteriaceae (30.8%) in
Irish samples. Authors only found higher
abundance of Escherichia coli in cases compared
with healthy controls.
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Table 1. Cont.
Study Sampling Materials and Site Microbiota Detection and OTUPicking Method * Sample Size Main Findings
Bard et al., 2015 [62] Feces from women withbreast cancer
PCR targeting 16S rRNA gene
sequences, not specified
32 women with BC [invasive
ductal (81%), stage 0 (46.9%),
grade II (62.5%), ER/PgR +
(80%), HER2 + (15%)]
Absolute numbers of Bifidobacterium and
Blautia, and proportion of F Prausnitzii and
Blautia were significantly different according to
clinical stages. Women with grade III had
increased absolute numbers of Blautia sp.
compared to women with grade I.
Significant differences were also found in the
absolute numbers of total bacteria and some
bacterial groups (F prausnitzii, Firmicutes,
Blautia and Egerthella), according to BMI.
Goedert et al., 2015 [52] Urine and feces of cases andcontrol women
Illumina sequencing and taxonomy
V3-V4 16S rRNA genes, QIIME:
OTUs were assigned to taxa by
matching to the Ribosomal Data
Project naïve Bayesian classifier,
specific method not disclosed
48 BC postmenopausal women
[ER+ (n = 42), PR+ (n = 37) and
HER2+ (n = 5)] and 48 paired
control women
Compared with control women, case patients
had an altered fecal microbiota composition
(β-diversity) and a lower α-diversity,
which was estrogen-independent. Relative
abundance of several taxa differed between
cases and control: case patients had higher
levels of Clostridiaceae, Faecalibacterium,
and Ruminococcaceae; and lower levels of Dorea
and Lachnospiraceae. Cases presented higher
urinary estrogen levels. Total urinary estrogens
significantly correlated with α-diversity in
controls but not in cases patients.
Banerjee et al., 2015 [64]
Breast tissue from TNBC cases,
and from matched and
non-matched controls. Controls
samples obtained from the
adjacent non-cancerous breast
tissue of the same patient,
and from healthy individuals
(non-matched)
PathoChip array
TNBC (n = 100) and matched
controls (n = 17) and
non-matched controls (n = 20),
from the Abramson Cancer
Center Tumor Tissue and
Biosample.
TNBC samples presented a specific microbial
signature of viruses, bacteria, fungi and
parasites which was underrepresented in
normal tissue. This signature was significantly
associated with the cancer samples. In the viral
signatures Herpesviridae, Retroviridae,
Parapoxviridae, Polyomaviridae, Papillomaviridae
families were detected. In the bacterial
signatures the highest prevalence
was Arcanobacterium
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Table 1. Cont.
Study Sampling Materials and Site Microbiota Detection and OTUPicking Method * Sample Size Main Findings
Chan et al., 2016 [65] Nipple aspirate fluid (NAF) andaerolar breast skin
16S-V4 rRNA gene amplicon
sequencing, Mothur: sequences
were aligned to SILVA v119, specific
method not disclosed
Women with breast ductal
cancer (25 cases), and healthy
women (23 controls)
The NAF microbial community composition
was different in women with BC.
These microbes showed β-glucuronidase
activity. The most abundant bacteria in NAF
samples were those belonging to Firmicutes,
Proteobacteria, and Bacteroidetes phyla. In NAF
from BC, there was relatively higher incidence
of Alistipes, and an unclassified genus from the
Sphingomonadaceae family in NAF from healthy
women. The areolar skin microbota in BC and
HC were not significantly distinguishable.
Hieken et al., 2016 [66]
Breast tissue and breast skin
from patients undergoing
non-mastectomy breast surgery
for cancer or benign disease
16S V3-V5 rDNA hypervariable taq
sequencing, IM-TORNADO:
Taxonomy was assigned against a
Greengenes reference database,
specific method not disclosed
Patients with benign breast
disease (n = 13) and invasive
breast cancer (n = 15); all
ER/PR+, HER-2+ (29%)
Breast tissue had its own microbiome, different
from the overlying breast skin. Moreover,
breast microbiome in women with cancer was
notably different from the breast microbiome
of women with benign disease.
The microbiome from breast tissue was
differentially abundant of phyla Firmicutes,
Actinobacteria, Bacteroidetes, and Proteobacteria.
BC correlated with enrichment in taxa of lower
abundance of Fusobacterium, Atopobium,
Gluconacetobacter, Hydrogenophaga and
Lactobacillus genera.
Urbaniak et al., 2016 [67]
Breast tissue from women with
breast cancer (lumpectomies or
mastectomies) or healthy
women (breast reductions
or enhancements)
16S V6 rRNA amplicon sequencing,
QIIME: OTU were made by
extracting the best hits from the
SILVA database. The 16S rRNA
sequences obtained in this study
have been deposited in the Short
Read Archive at NCBI.
58 women with benign (n = 13)
or BC (n = 45), and 23 controls
(n = 23)
Bacterial profiles were statistically different in
normal adjacent tissue from BC women
compared with control tissue. The comparison
showed significantly higher relative
abundance of Prevotella, Lactococcus,
Streptococcus, Corynebacterium, and Micrococcus
in healthy patients, and Bacillus, Staphylococcus,
Enterobacteriaceae (unclassified), Comamondaceae
(unclassified) and Bacteroidetes (unclassified)
in BC.
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Table 1. Cont.
Study Sampling Materials and Site Microbiota Detection and OTUPicking Method * Sample Size Main Findings
Yazdi et al., 2016 [68] Sentinel lymph nodes andnormal adjacent breast tissue RT-PCR and pyrosequencing
123 sentinel lymph nodes and
123 normal adjacent breast
tissue specimens
There were significant differences between
lymph cancer nodes and normal samples
according to the presence of
Methylobacterium Radiotolerance.
Luu et al., 2017 [48] Feces from women withearly-stage breast cancer Real-time qPCR
31 women with BC [ER/PgR+
(90%), HER2+ (15%)]
In the fecal samples, Firmicutes and
Bacteroidetes phyla were the most abundant
bacteria. The total number (richness) of
Bacteroidetes, Clostridium coccoides cluster, C.
leptum cluster, F. prausnitzii, and Blautia spp.
were significantly higher in clinical stage
groups II/III than in clinical stages 0/I. Blautia
spp. was associated with a more severe
histoprognostic grades. Moreover, total
bacteria and three groups: Firmicutes,
Faecalibacterium prausnitzii and Blautia spp.
showed lower number in overweight and
obese women.
Wang et al., 2017 [45]
Urine, and right and left breast
tissue from each control patient,
and tumor and ipsilateral
adjacent normal breast tissue
for cases
Illumina 16S V3-V4 rRNA
amplification, UCLUST: OTUs were
assigned using Greengenes, specific
method not disclosed
50 BC patients and 20
healthy controls
Neither significant difference in overall
diversity (Shannon diversity) nor in microbiota
content (number of observed OTUs) was
detected in breast tissue from cancer or control
women. However, significantly decreased
relative richness of Methylobacterium was
found in women with BC.
Differences in the urinary microbiota of
women with BC were detected, with increased
abundance of Corynebacterium, Staphylococcus,
Actinomyces, and Propionibacteriaceae
gram-positive bacteria, and decreased
abundance of genus Lactobacillus.
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Table 1. Cont.
Study Sampling Materials and Site Microbiota Detection and OTUPicking Method * Sample Size Main Findings
Thompson et al., 2017 [69]
Breast tumor tissues and normal
adjacent tissues from The
Cancer Genome Atlas
16S-V3-V5 rRNA amplified,
metagenomeSeq package, specific
method not disclosed
668 tumor tissues (HER2+, ER+
and TNC BC) and 72 normal
adjacent tissues
The most abundant phyla in breast tissues
were Proteobacteria, Actinobacteria,
and Firmicutes. In tumor samples, the most
predominant phylum was Proteobacteria,
and Actinobacteria in normal tissue.
Mycobacterium fortuitum and Mycobacterium
phlei were two of the prevalent species
observed differentially abundant in the tumor
samples. Escherichia coli was also more
prevalent in the breast tissues.
Goedert et al., 2018 [53]
Urine and feces from
postmenopausal BC cases and
control women
16S V4 rRNA gene amplicon
sequencing, DADA2 package and
SILVA. The 16S rRNA gene
sequence data and case–control
status have been deposited and are
available in the Sequence Read
Archive under BioProject ID
PRJNA383849
48 BC postmenopausal women
[ER+ (n = 42), PR+ (n = 37) and
HER2+ (n = 5)] and 48 paired
control women
Cases had reduced richness (number of
species) and α-diversity, significantly more
marked in the IgA-positive gut microbiota.
Cases showed higher levels of Clostridiaceae,
Faecalibacterium, and Ruminococcaceae; and
lower levels of Dorea and Lachnospiraceae.
Cases versus controls showed significant and
different estrogen-independent associations
with the IgA+ and IgA− gut microbiota.
Total urinary estrogens correlated with
α-diversity only in controls.
Banerjee et al., 2018 [70]
BC tissues (cases), breast control
tissues from healthy individuals
(reduction surgeries)
PathoChips array
BC [ER+ (n = 50), HER2+
(n = 34), triple positive (n = 24),
TNBC (n = 40)], and normal
breast tissue (n = 20)
Unique viral, bacterial, fungal and parasitic
signatures were found for each of the BC types.
The triple negative and positive samples
showed distinct microbial signature patterns
than the ER and HER2 positive breast cancer
samples. The most prevalent bacterial
signatures were for Proteobacteria followed by
Firmicutes. The Mobiluncus family was detected
in all four types.
BC: breast cancer; DADA2: Divisive Amplicon Denoising Algorithm; EM: estrogens metabolites; ER+: estrogen receptor-positive; HC: healthy control; HER2+: human epidermal growth
factor receptor 2-positive; NAF: nipple aspirate fluid; OTUs: operational taxonomic units; PR+: progesterone receptor-positive; QIIME: Quantitative Insights Into Microbial Ecology; TNB:
triple negative breast cancer. * All studies with OTU picking method have rarefaction curves assays.
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Firmicutes and Bacteroidetes phyla were also the most numerous bacteria observed in the feces
of 31 women with early-stage breast cancer [48]. This study evaluated the relationship between
the composition of gut microbiota with the clinic-biological characteristics of BC, describing that
the total number of Bacteroidetes, Clostridium coccoides cluster, C. leptum cluster, F. prausnitzii,
and Blautia spp. were significantly higher in clinical stage groups II/III than in clinical stages 0/I,
and that Blautia spp. were higher in the more severe histoprognostic grade cases. Moreover, authors
found a significant decline in the abundance of total bacteria and in three bacterial groups (Firmicutes,
Faecalibacterium prausnitzii, and Blautia) as a function of the BMI of participants, with lower number of
bacteria in overweight and obese patients [48].
4. Mammary Microbiota and Breast Cancer
Some authors have also raised the question of the role of the mammary microbiome in modulating
the risk of breast cancer development. The hypothesis is that changes in the composition of breast
microbiota may also contribute to disease development and progression through several pathways,
but it is still unclear whether the host´s microbial differences are a consequence or a cause of this
human disease [52,63,67,71]. It is also still unclear whether there is a specific microbial signature
(either for the presence of pathogenic strains or the absence of beneficial ones) responsible of breast
carcinogenesis. The results of clinical studies on the relationship between mammary microbiota and
BC are also included in Table 1.
The human breast is not sterile but contains a diverse and unique community of bacteria, distinct
from that found at other body sites, regardless of the location sampled within the breast, age, country of
origin, history of pregnancy, presence/absence of breast malignancy, and method of DNA preparation
and sequencing technologies [44,63,71]. To date, several findings seem to demonstrate the potential
origin of part of the breast tissue microbiome, by translocation from the gastrointestinal tract, in
addition to the skin, via the nipple-areolar orifices, nipple-oral contact via lactation and/or sexual
contact [66]. In this regard, it has been proposed that this breast microbiome contributes to maintenance
of healthy breast tissue by stimulating, for example, resident immune cells, although the type of bacteria
and their metabolic activity, such as the ability to degrade carcinogens, may also contribute [44].
Only few studies have characterized which bacteria are present in breast tumor tissue and
normal adjacent tissue of women, finding mixed results in the breast tissue microbiota of patients
with and without cancer. These investigations are still in their infancy, and the evidence remains
unclear on whether a difference exists between tumor and adjacent histologically-normal tissue from
cancer patients. Thus, some studies by Urbaniak et al. have shown that bacterial communities
do not differ between tumor tissue and normal adjacent tissue, at both population an individual
level [63,67]. Nevertheless, these authors found a higher abundance of Escherichia coli, known for its
cancer-promoting activity, in women with cancer compared with healthy controls.
Xuan et al. [44] also found that the amount of bacteria was not significantly different in paired
normal tissue from BC patients and healthy breast tissue from healthy individuals. The number
of OTUs detected did not vary between paired normal and tumor tissue, indicating no significant
difference in richness [44]. However, breast tumor tissue had significantly reduced amounts of
bacteria: the evenness of the communities was significantly different (p = 0.01). Of the 1614 OTUs
detected, 11 OTUs were differentially abundant (p < 0.05). Of those 11 OTUs, 8 were more abundant
in paired normal tissue and 3 were more abundant in tumor tissue. Xuan et al. [44] observed
differential abundance with the genera Methylbacterium and Sphingomonas between paired healthy
and/or normal adjacent tissue and tumor tissue, suggesting a potential role of those in cancer
development. Methylobacterium radiotolerans was relatively enriched and the most prevalent bacterium
(found in 100% of samples) in tumor tissue, while Sphingomonas yanoikuyae was relatively enriched,
the most prevalent (found in 95% of samples) and with absolute levels significantly higher in paired
normal tissue. Sphingomonas yanoikuyae was not present in the corresponding tumor tissue. The relative
abundances of these two bacterial species were inversely correlated in paired normal breast tissue but
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not in tumor tissue, indicating that dysbiosis may be associated with BC. M. radiotolerans was detected
in all samples, but its absolute levels did not vary significantly between paired normal and tumor
tissue, meaning that its higher relative abundance in tumor tissue reflects a decrease in other bacteria
present and not an increase in the absolute level of the organism [44].
Most of the works dealing with the microbiome of breast tissue describes a community
characterized by a predominance of the phyla Proteobacteria and Firmicutes [44,63,67], with the
exception of one study that found a predominance of Bacteroidetes and very little Proteobacteria [66].
Urbaniak et al. [63] studied whether there was a specific microbiome within the mammary tissue,
and whether the microbes were different in the breast tissue of 81 women from Canada and Ireland,
with and without cancer. A diverse population of bacteria was detected within tissue collected from
sites all around the breast. Proteobacteria and Firmicutes were the most abundant phyla in breast
tissue, compared with other taxonomic groups. Authors justified these findings due to a probable
host microbial adaptation to the fatty acid environment in the breast tissue. The main OTUs found
belonged to 7 different phyla, Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Deinococcus-Thermus,
Verrucomicrobia, and Fusobacteria, with Proteobacteria being the most abundant, followed by Firmicutes
(specifically from the class Bacilli). An additional important finding was the geographical difference
between the Canadian and Irish breast tissue microbiomes. Thus, the most abundant taxa in
the Canadian samples were Bacillus (11.4%), followed by Acinetobacter (10.0%); and unclassified
Enterobacteriaceae (30.8%), Staphylococcus (12.7%), Listeria welshimeri (12.1%), Propionibacterium (10.1%),
and Pseudomonas (5.3%) in the Irish samples [63]. However, these differences may be erroneous as the
tissue samples were processed in different laboratories using different protocols and reagents.
Urbaniak et al. [67] also showed that there are different bacterial profiles in breast tissue of
healthy women and those with breast cancer [67]. Similarly, Hieken et al. [66] found that the
breast microbiome in women with malignant disease was notably different from that of women
with benign disease. The comparison of normal adjacent tissue from women with BC and tissue from
healthy women showed significantly higher relative abundances of Prevotella, Lactococcus, Streptococcus,
Corynebacterium, and Micrococcus in healthy patients, and Bacillus, Staphylococcus, Enterobacteriaceae,
Comamondaceae, and Bacteroidetes in BC patients. These bacteria had the ability to cause DNA damage
in vitro. Additionally, there was a decrease in some lactic acid bacteria, known for their beneficial
health effects, including anti-carcinogenic properties [72].
Wang et al. [45] reported no major shifts in overall diversity or microbiota content when they
compared 57 patients with breast invasive carcinoma and 21 healthy paired normal tissues from
women undergoing breast surgery for cosmetic purposes. In cancer patients, adjacent histologically
normal and non-cancer samples showed no significantly differences in Shannon diversity index
or number of observed OTUs. These data are consistent with Urbaniak et al.’s findings [67] but
disagree with those of Xuan et al. [44]. Nevertheless, cancer patient breast tissue microbiota clustered
significantly differently from non-cancer patients (p = 0.03), mainly due to the fact that breast tissue
in cancer patients exhibited a significantly decreased relative abundance of Methylobacterium (while
this was increased at the site of the tumor in the study of Xuan et al. [44]; median 0.10 vs. 0.24,
p = 0.03). These differences were higher in the microbiota of urine from cancer patients, characterized
by increased levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces,
and Propionibacteriaceae, and decreased abundance of Lactobacillus. If these data are confirmed in large
cohort studies, it would serve to identify possible sites of dysbiosis distant from the breast tissue as a
non-invasive biomarker of breast cancer [45].
In contrast to the aforementioned findings, Hieken et al. [66] identified significantly distinct
microbial communities in the normal breast tissue adjacent to invasive cancer compared to that of
normal breast tissue adjacent to benign disease. An overview of taxonomic profiles showed that the
overal microbiota of breast tissue between the two disease states appear to be similar, dominated
by Bacteroidetes and Firmicutes, the same most abundant phyla reported by Urbaniak et al. [63,67].
Neither α-diversity nor the Shannon index showed significant differences; however, β-diversity
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revealed that the microbial community in breast tissue adjacent to invasive cancer was significantly
different from that of women with benign disease, mainly in rare and/or less abundant lineages.
Malignancy correlated with enrichment in taxa of lower abundance including the genera Fusobacterium,
Atopobium, Gluconacetobacter, Hydrogenophaga and Lactobacillus. Authors attributed the age and
menopausal status of patients as potentially confounders of the identified differences. These specific
genus-level has been reported in association with other epithelial malignancies, including colon
cancer [73].
The microenvironment in and around the tumor contains a variety of cell types, including the
microbiota. Pathophysiological changes occurring in the cells and in the microbial composition could
also have a significant impact on the tumor growth [27]. Microbial contribution to the breast tumor
microenvironment has been less investigated [44,45,69]. Thompson and co-workers [69] characterized
the breast microbiota in 668 breast tumor tissues and 72 non-cancerous adjacent tissues, from The
Cancer Genome Atlas, and reported possible microbial compositional shifts among the disease
subtypes. The most prevalent phyla in the tumor sites were Proteobacteria (48.0%), Actinobacteria
(26.3%) and Firmicutes (16.2%), findings consistent with previous results from Hieken et al. [66] and
Urbaniak et al. [67]. Mycobacterium fortuitum and Mycobacterium phlei were two of the prevalent species
differentially abundant in tumor samples. Proteobacteria also showed increased presence among tumor
tissues, and Actinobacteria in non-cancerous adjacent tissues tissue samples [69].
In addition to breast and tumor tissue, nipple aspirate fluid (a natural secretion produced by breast
epithelial cells) collected from breast cancer patients has been shown to have a significantly different
microbiota profile compared to that collected from healthy volunteers [74]. One study investigated the
breast ductal microbiota by characterizing the microorganisms present in nipple aspirate fluid from BC
women (ductal carcinomas) and healthy control women [65]. Authors found that the nipple aspirate
fluid community composition was different (β-diversity) in women with BC. Having a history of breast
cancer significantly affected the nipple aspirate fluid microbial composition and explained 13.5% of the
variation among the samples. The most abundant bacteria phyla were Firmicutes (42.1%), Proteobacteria
(32.9%), and Bacteroidetes (14.5%). In nipple aspirate fluid collected from BC, there was relatively higher
incidence of the genus Alistipes. By contrast, an unclassified genus from the Sphingomonadaceae family
was relatively more abundant in nipple aspirate fluid from healthy control women [65].
The bacterial composition and diversity of sentinel lymph nodes of BC patients were also
investigated by Yazdi and co-workers in 123 sentinel lymph nodes, 123 normal adjacent breast tissue
specimens and 5 normal mastectomy samples. Authors showed an increased presence of Methyl
bacterium radiotolerance in sentinel lymph nodes [68].
Along with the presence of signatures for bacteria, parasites and fungi, a substantial presence
of viruses in the breast tumor tissue and/or tumor microenvironment have also been confirmed,
and some authors have suggested that many of these viral signatures could be associated with specific
breast cancer subtypes [70]. For example, Banerjee and co-workers found predominant viral, bacterial,
fungal and parasitic genomic sequences signatures, significantly present in the analysis of 100 triple
negative breast cancer samples, which was underrepresented in the controls normal tissue (17 matched
and 20 non-matched controls). Bacterial probes included representatives of a number of families
(Actinomycetaceae, Caulobacteriaceae, Sphingobacteriaceae, Enterobacteriaceae, Prevotellaceae, Brucellaceae,
Bacillaceae, Peptostreptococcaceae, Flavobacteriaceae), some of which have been associated with cancers [64].
When authors investigated the diversity of the microbiome in the four major types of breast cancer
(endocrine receptor (ER) positive, triple positive, HER2+ positive and triple negative breast cancers),
two distinct and significantly different patterns were detected, one for the triple negative and triple
positive breast cancer types, and another for the ER+ and HER2+ positive breast cancer samples,
compared to healthy breast control tissue [70]. Additionally, each type of BC held signatures for unique
bacterial genera. Nevertheless, there were a number of bacterial families present in all four breast
cancer types: predominantly Proteobacteria followed by Firmicutes and Actinomyces.
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5. Functional Pathways
More important as a cancer risk and promoting factor than the microbiota composition is its
functionality. Several possible mechanisms have been proposed to understand the microbial influence
on breast cancer.
5.1. Regulation of Chronic Inflammation and Immunity
The microbiota might promote malignancy by inducing chronic inflammation, by altering the
balance of host cell proliferation and death, and by triggering uncontrolled innate and adaptive
immune responses [27]. Increased BC risk has been associated with the presence of chronic, persistent,
and dysregulated inflammation [75,76]. For instance, one postulated inflammation-related mechanism
for breast cancer is upregulation of cyclooxygenase 2 (COX2) and its product, prostaglandin E2 (PGE),
which results in increased aromatase expression in adipose tissue and increased conversion of androgen
precursors to estrogens [77,78]. In this regard, the use of some non-steroidal anti-inflammatory
drugs has been associated with a reduced risk of estrogen receptor (ER)-positive BC incidence or
recurrence [79–85].
A potential inflammatory biomarker is mucosal secretory immunoglobulin A (IgA), essential in
maintaining the integrity of the mucosal barrier by recognizing and regulating the composition of the
gut microbial community, therefore reducing their fitness and mitigating the host’s innate immune
response [86]. The link between BC and the mucosal secretory IgA has been established [53]. This host
mechanism limits the access of intestinal antigens to the circulation and limits the invasiveness of
potentially dangerous bacterial species [87]. Besides, the microbiota itself represents a functional
luminal barrier [88] by maintaining epithelial cell turnover, by mucin production and by competing
for resources, thereby suppressing the growth of pathogens.
Some particular microbiota may also have a role in maintaining healthy breast tissue through
stimulation of host inflammatory responses. For instance, the presence of the specific bacterium
S. yanoikuyae in breast tissue of healthy women was associated with a dramatic reduction in its
abundance in the corresponding tumor tissue. This increase may lead to decreased bacterial-dependent
immune cell stimulation, resulting in a permissive environment for breast tumorigenesis [44].
Several researches have exanimated the role of microbiota in the regulation of specific processes
of immunity in the context of cancer development. For example, Lactococcus spp. may modulate
cellular immunity by maintaining the cytotoxic activity of resident Natural Killer (NK) cells [89],
and Lactococcus lactis has been shown to activate vital cells related with tumor growth (murine splenic
NK cells), enhancing cellular immunity [90].
5.2. Genomic Stability and DNA Damage
Although DNA damage may not be sufficient in itself to promote cancer development,
double-strand breaks are the most detrimental type of DNA damage caused by genotoxins, reactive
oxygen species, and ionizing radiation [91]. Urbaniak et al. [67] examined the ability to induce DNA
double-stranded breaks of all bacteria isolates cultured from normal adjacent tissue of breast cancer
patients. They found that several Escherichia coli (a member of the Enterobacteriaceae family) isolates
and one Staphylococcus epidermidis isolate displayed this ability through the production of colibactin,
which could cause genomic instability. Neither Bacillus isolates nor Streptococcus thermophilus induced
double-strand breaks, thus protecting against DNA, which may be explained by their production of
anti-oxidant metabolites that neutralize peroxide and superoxide radicals [72].
5.3. Metabolic Function
Some differentially abundant pathways have been investigated in breast cancer patients,
mainly involving hormone metabolism (estrogens and progesterone), cysteine and methionine
Int. J. Environ. Res. Public Health 2018, 15, 1747 15 of 20
metabolism, glycosyltransferases, fatty acid biosynthesis and metabolism, and C5-branched dibasic
acid metabolism [92,93].
Thus, many of the microbes related with BC share the β-glucuronidase enzymatic activity
mentioned above, which hinders the conjugation of estrogens, among other compounds, and leaves
them as biologically active hormones. The perturbation of this estrobolome has been shown to influence
both local and systemic levels of estrogen and its metabolites [13,94]. Malignant tissue in ER+ BC
contains higher levels of estrogen metabolites as compared to normal breast tissue, attributed in part
to altered intracrine signaling [95]. β-Glucuronidase prevalence was also found in nipple aspirate
fluid of breast cancer survivors [65]. Many β-glucuronidase bacteria are found in two dominant
subgroups, namely the Clostridium leptum cluster and the Clostridium coccoides cluster, which belong
to the Firmicutes phylum. The Escherichia/Shigella bacterial group, a member of the Proteobacteria
phylum, also possesses β-glucuronidase enzymes [51]. Some studies have shown positive correlations
between the abundance of Streptococcus and the presence of β-glucuronidase and/or β-glucosidase
enzymes [96].
β-Glucuronidase could also play a major role in the deconjugation of endocrine disrupting
chemicals, such as bisphenol-A, increasing the time that they remain in the organism. Some endocrine
compounds could induce alterations in the gut microbiota and the metabolites they produce,
which may be associated with increased inflammation [97].
6. Conclusions
The association between women’s microbiota and BC has been explored to a certain extent
to date. However, it is still unclear whether the host’s microbiota is causative or contributory to
this disease. It is worth pointing out that most of the data available at this time suggest the role
of specific microbial agents present in the breast and/or gut microenvironment on this disease.
The exact mechanisms underlying the clinical observations described in this review remain to be
fully understood. The studies published so far utilize a wide range of DNA extraction methods,
amplification primers, sequencers, bioinformatics pipelines, and patient populations impairing the
comparison of data. Therefore, new computational approaches (ASVs) that scale linearly with study
size, simple merging between independently processed data sets, and forward prediction including
accurate measurement of diversity and applicability to communities lacking deep coverage in reference
databases are needed [23].
Further studies examining whole microbiota composition and function would provide vital
information on its role in breast health. To define specific microbial signatures for BC patients may
also have implications for future diagnostic development as well as for therapeutic interventions [98].
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